Cara Therapeutics Inc (NASDAQ:CARA) – Analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for Cara Therapeutics in a note issued to investors on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst C. Russo anticipates that the biopharmaceutical company will earn ($1.81) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $24.00 target price on the stock.
CARA has been the subject of a number of other research reports. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 price target on shares of Cara Therapeutics in a research note on Friday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target (up previously from $20.00) on shares of Cara Therapeutics in a research note on Tuesday, January 31st. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 14th. Vetr upgraded shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $18.44 price target for the company in a research note on Wednesday, April 5th. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of Cara Therapeutics in a research report on Friday, March 10th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Cara Therapeutics presently has an average rating of “Buy” and an average price target of $24.95.
ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/04/21/cantor-fitzgerald-weighs-in-on-cara-therapeutics-incs-fy2017-earnings-cara-updated-updated.html.
Shares of Cara Therapeutics (NASDAQ:CARA) traded down 3.28% during trading on Thursday, reaching $16.53. 1,978,207 shares of the company’s stock were exchanged. The stock’s market cap is $451.32 million. Cara Therapeutics has a 12-month low of $4.35 and a 12-month high of $20.90. The company has a 50 day moving average of $17.26 and a 200 day moving average of $12.41.
Institutional investors have recently made changes to their positions in the stock. Creative Planning boosted its position in shares of Cara Therapeutics by 9.3% in the first quarter. Creative Planning now owns 14,340 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 1,215 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Cara Therapeutics by 8.3% in the fourth quarter. Teachers Advisors LLC now owns 33,390 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 2,552 shares in the last quarter. Chescapmanager LLC purchased a new position in shares of Cara Therapeutics during the fourth quarter valued at about $6,365,000. Flinton Capital Management LLC purchased a new position in shares of Cara Therapeutics during the fourth quarter valued at about $139,000. Finally, Disciplined Growth Investors Inc. MN purchased a new position in shares of Cara Therapeutics during the fourth quarter valued at about $8,251,000. 43.29% of the stock is currently owned by institutional investors.
In other news, major shareholder Ventures Vi Lp Rho acquired 500,000 shares of the company’s stock in a transaction on Friday, March 31st. The shares were bought at an average cost of $18.19 per share, with a total value of $9,095,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 7.70% of the stock is owned by corporate insiders.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Cara Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc and related companies.